Invesco provides investment-management services to retail (70% of managed assets) and institutional (30%) clients... Show more
In recent trading sessions, Invesco Ltd. (IVZ) stock has demonstrated resilience, maintaining levels above key support amid a volatile market environment. The shares have benefited from broader financial sector strength and anticipation surrounding upcoming results, even as assets under management faced headwinds from outflows and equity market dips. Trading within a tightened range, IVZ reflects investor confidence in the firm's long-term inflow trends and diversified offerings, positioning it steadily through the latest market cycle. Volume remains consistent with averages, underscoring sustained interest as the stock navigates macroeconomic shifts.
Tickeron's Trending AI Robots page curates the top 25 performers from over 350 AI trading bots designed to trade thousands of tickers across stocks, ETFs, and crypto. These bots employ advanced AI and machine learning for real-time signals, featuring diverse strategies like trend-following, multi-agent systems, long/short pairs, and corridor take-profit/stop-loss exits. Performance stats are compelling: annualized returns range from 15% to 167%, win rates from 48% to 88%, and profit factors up to 11.7, with average trade durations of 1-8 days on 5-60 minute timeframes. Finance sector bots target tickers like GS, MS, SCHW, and regional banks, offering styles suited to volatile conditions. Explore these curated tools to identify bots aligning with your risk tolerance and market outlook.
Invesco Ltd. (IVZ) has experienced measured price movements in recent weeks, influenced by key updates on assets under management, analyst revisions, and earnings anticipation. On April 10, the company reported preliminary March 31 AUM of $2.159 trillion, down 4.4% from February's levels. This decline stemmed primarily from market depreciation and $1.8 billion in money market outflows, though long-term net inflows of $0.3 billion provided a counterbalance. ETFs and index strategies AUM dropped 5% to $638 billion, while fundamental equity fell to $288 billion and fixed income to $313 billion. The report tempered enthusiasm, contributing to short-term pressure, yet shares held firm, rising over 4% weekly thereafter as focus shifted to underlying positives.
Analyst actions added nuance. On April 24, JPMorgan maintained a Neutral rating but cut its price target from $30 to $25, citing fee compression risks. Similar trims came from Morgan Stanley (to $26) and TD Cowen (to $27 from $34.50), reflecting concerns over persistent outflows despite a robust 52-week gain from $13.46 lows. Nonetheless, the consensus remains Buy, with 15 analysts averaging $27 targets (range $24-$33), implying modest upside. These updates prompted intraday volatility but did not derail the uptrend, as IVZ outperformed peers like BEN amid sector rotation.
Building momentum centers on the Q1 2026 earnings release scheduled for April 28. Wall Street anticipates EPS of $0.58 (up 31% quarter-over-quarter) and $1.27 billion in revenue, following Q4 2025's EPS beat of $0.62 versus $0.58 expected. Positive long-term flows and ETF growth underpin optimism, countering money market drags. Peers' reports, such as SEI Investments' AUM rise, reinforced sector stability. Overall, these factors have sustained IVZ's climb to around $25.50, with market behavior linking dips to AUM news and rebounds to earnings prospects and historical beats.
As Invesco Ltd. progresses through 2026, investors should track themes of market resilience outlined in the firm's annual investment outlook, which anticipates further global stock advances and U.S. interest rate cuts supporting asset growth. Key opportunities lie in expanding ETFs and index strategies, which comprise a significant AUM portion, alongside sustained long-term inflows amid diversifying client bases. However, risks include persistent money market outflows, fee pressures from passive competition, and sensitivity to equity market volatility impacting AUM valuations.
Strategic factors to monitor encompass regulatory shifts in asset management, technological integrations for operational efficiency, and macroeconomic influences like inflation trajectories and monetary policy. Competitive positioning versus larger peers will hinge on performance in fixed income and alternatives, where top-quartile results could drive organic growth. Balanced against cost discipline, these elements will shape IVZ's trajectory in a rebalancing market environment.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
IVZ saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on June 01, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 47 instances where the indicator turned negative. In of the 47 cases the stock moved lower in the days that followed. This puts the odds of a downward move at .
The 10-day RSI Indicator for IVZ moved out of overbought territory on May 14, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where IVZ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVZ declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
IVZ broke above its upper Bollinger Band on May 11, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Momentum Indicator moved above the 0 level on May 28, 2026. You may want to consider a long position or call options on IVZ as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IVZ advanced for three days, in of 322 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 223 cases where IVZ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.244) is normal, around the industry mean (3.934). P/E Ratio (19.476) is within average values for comparable stocks, (25.672). Projected Growth (PEG Ratio) (0.383) is also within normal values, averaging (1.708). Dividend Yield (0.031) settles around the average of (0.092) among similar stocks. P/S Ratio (1.888) is also within normal values, averaging (17.397).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating outstanding price growth. IVZ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVZ’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 79, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of investment management services
Industry InvestmentManagers